• No results found

[PDF] Top 20 LDL Cholesterol Lowering in Type 2 Diabetes: What Is the Optimum Approach?

Has 10000 "LDL Cholesterol Lowering in Type 2 Diabetes: What Is the Optimum Approach?" found on our website. Below are the top 20 most common "LDL Cholesterol Lowering in Type 2 Diabetes: What Is the Optimum Approach?".

LDL Cholesterol Lowering in Type 2 Diabetes: What Is the Optimum Approach?

LDL Cholesterol Lowering in Type 2 Diabetes: What Is the Optimum Approach?

... Diabetes carries an exceptionally high burden of disease, including a higher mortality from CVD. Primary cardiovas- cular prevention is particularly important in this population because diabetic individuals ... See full document

6

Lowering low-density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus

Lowering low-density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus

... Notes: (A) BA metabolic pathway. (B) Lipid-lowering MOA of BASs. BASs bind to BAs in the intestine, which increases BA elimination via fecal excretion. The reduction in the BA pool reduces nuclear receptor ... See full document

10

Prescription of lipid lowering medications for patients with type 2 diabetes mellitus and risk associated LDL cholesterol: a nationwide study of guideline adherence from the Swedish National Diabetes Register

Prescription of lipid lowering medications for patients with type 2 diabetes mellitus and risk associated LDL cholesterol: a nationwide study of guideline adherence from the Swedish National Diabetes Register

... than LDL-C values alone. Previously, the clinical value of LDL-C as a risk marker for CVD has been discussed and the ratio of non-HDL to HDL cholesterol has been shown to be a better measure for ... See full document

10

A pilot study of ezetimibe vs. atorvastatin for improving peripheral microvascular endothelial function in stable patients with type 2 diabetes mellitus

A pilot study of ezetimibe vs. atorvastatin for improving peripheral microvascular endothelial function in stable patients with type 2 diabetes mellitus

... for LDL-lowering therapy on peripheral microvascular endothelial function in stable patients with type 2 ...with type 2 DM and mildly elevated LDL (LDL >120 ... See full document

10

Implications of the obesity epidemic for lipid-lowering therapy: Non-HDL cholesterol should replace LDL cholesterol as the primary therapeutic target

Implications of the obesity epidemic for lipid-lowering therapy: Non-HDL cholesterol should replace LDL cholesterol as the primary therapeutic target

... of type 2 diabetes in the 1990s has doubled when compared to the 1970s, with most of the absolute increase in diabetes incidence occurring in the obese as determined by body mass index (BMI) ... See full document

14

Serum butyrylcholinesterase in type 2 diabetes mellitus: a biochemical and bioinformatics approach

Serum butyrylcholinesterase in type 2 diabetes mellitus: a biochemical and bioinformatics approach

... BChE breaks down ester type of neuromuscular blocking agents used in anesthesia [4]. It may also play a role in lipid metabolism [5], and may be affected by dietary fat [6]. Similarly, diabetes mellitus has ... See full document

5

Dose-dependent LDL-cholesterol lowering effect by plant stanol ester consumption: clinical evidence

Dose-dependent LDL-cholesterol lowering effect by plant stanol ester consumption: clinical evidence

... yoghurt type drink with added plant stanol ester effectively reduce serum total cholesterol and ...significant LDL-C lowering effect of about 10% can be achieved by a daily intake of plant ... See full document

7

Impact of Glucose-Lowering Medications on Cardiometabolic Risk in Type 2 Diabetes

Impact of Glucose-Lowering Medications on Cardiometabolic Risk in Type 2 Diabetes

... In this respect, Incretin-Based Therapies (IBTs), including Glucagon Like Peptide-1 Receptor Agonists (GLP-1RA), DiPeptidyl Peptidase-4 inhibitors (DPP-4is), and Sodium/GLucose coTransporter 2 inhibitors ... See full document

18

Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study

Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study

... Sabatine et al. have reported that EVO reduced the level of LDLC by 61% from a median of 120 to 48 mg/dl. The rate of cardiovascular events at 1 year was reduced from 2.18% in the standard therapy group to 0.95% in the ... See full document

11

Serum resistin is associated with C reactive protein and LDL  cholesterol in type 2 diabetes and coronary artery disease in a Saudi population

Serum resistin is associated with C reactive protein and LDL cholesterol in type 2 diabetes and coronary artery disease in a Saudi population

... Plasma samples were stored at -70°C prior to analysis. Measurements of serum cholesterol, HDL, and triglycer- ides, Apo AI and ApoAII were performed using routine laboratory methods. Insulin was analysed by a ... See full document

7

Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study

Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study

... Before 2013 [16], an LDLC target of <70 mg/dl was con- sidered to be optimal for patients at high risk of coronary heart disease, and/or for type II diabetics. In treated pa- tients from NHANES data, only 28% ... See full document

12

Ezetimibe and simvastatin for the prevention of cardiovascular events in predialysis chronic kidney disease patients: a review

Ezetimibe and simvastatin for the prevention of cardiovascular events in predialysis chronic kidney disease patients: a review

... Given the study was underpowered specifically for coronary events, we can conclude that there was a trend towards a significant decrease in these types of events when aggressively treating hyperlipidemia in CKD patients. ... See full document

5

A Web Based Cardiovascular Risk  Assessment via Pharmacists:  A Feasibility and Validation Study

A Web Based Cardiovascular Risk Assessment via Pharmacists: A Feasibility and Validation Study

... We developed a web-based online questionnaire (Health Audit http://www.net-care.ch/) that aims to help indi- viduals manage their own health through a CV risk factor evaluation by pharmacists. The Health Audit was ela- ... See full document

11

Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol &amp;ge;70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy

Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol &ge;70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy

... Methods: We applied US Food and Drug Administration (FDA) and insurance eligibility cri- teria for ALI and EVO to 1090 hypercholesterolemic patients serially referred over 3 years who then received ≥ 2 months ... See full document

7

Effects Of Tetracarpidium Conophorum - ‘Nigerian Walnuts’ On Blood Lipids, Lipoproteins And Glucose Values In Adult Nigerians

Effects Of Tetracarpidium Conophorum - ‘Nigerian Walnuts’ On Blood Lipids, Lipoproteins And Glucose Values In Adult Nigerians

... On the other hand, as biological detergents, bile acids are required for cholesterol solubilization and absorption in the intestine. Binding of bile acids to fiber decreases free bile acids for solublizing ... See full document

5

Synergistic effect of simvastatin and ezetimibe on lipid and pro-inflammatory profiles in pre-diabetic subjects

Synergistic effect of simvastatin and ezetimibe on lipid and pro-inflammatory profiles in pre-diabetic subjects

... to 2 groups that would receive ezetimibe 10 mg/day (n = 25) or simvastatin 20 mg/day (n = 25), preceded by a 2-week run-in ...in LDL-choles- terol ... See full document

7

Once-Weekly Glucose-Lowering Therapy for Type 2 Diabetes

Once-Weekly Glucose-Lowering Therapy for Type 2 Diabetes

... The weekly dosing schedule of exena- tide QW may be beneficial for many Figure 2. Change in A1C (A), percentage of patients achieving a target A1C of < 7% (B), and body weight (D) in the clinical trials of ... See full document

6

Prevalence of metabolic syndrome and the comparison of fasting plasma glucose and HbA1c as the glycemic criterion for MetS definition in non-diabetic population in Ghana

Prevalence of metabolic syndrome and the comparison of fasting plasma glucose and HbA1c as the glycemic criterion for MetS definition in non-diabetic population in Ghana

... type 2 diabetes mellitus (T2DM) patients were stratified by tertiles of 4.7% (3.3–4.8%), 5.4% (4.9–5.6%), and 5.8% (5.7–6.4%), individuals with HbA1c level within 5.7–6.4% had increased number of ... See full document

8

The association of dyslipidemia and obesity with glycated hemoglobin

The association of dyslipidemia and obesity with glycated hemoglobin

... creased LDL-C, TG and hypo-HDL are established markers for CAD ...lipid lowering agents as proposed by the National Cholesterol Education Program, ... See full document

7

Comparative Evaluation of Antioxidant Enzymes and Serum Selenium Levels in  Libyan Atherosclerotic Patients

Comparative Evaluation of Antioxidant Enzymes and Serum Selenium Levels in Libyan Atherosclerotic Patients

... atherosclerotic type-II diabetes mellitus and forty-one atheroscle- rotic non-diabetic age matched normal blood pressure controls were included in the ...Table 2. In type-II diabetes ... See full document

19

Show all 10000 documents...